Background: Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5HT)
transporter inhibitor as well as 5HT3A and 5HT7 receptors antagonist, 5HT1A and 5HT1B …

Introduction Vortioxetine is a multimodal-acting antidepressant that provides improvements
on cognitive function aside from antidepressants and anxiolytic effects. Vortioxetine has …

Objective To describe the efficacy and safety of vortioxetine for the treatment of major
depressive disorder (MDD). Data sources The pivotal registration trials were accessed by …

Background Vortioxetine is a novel multimodal compound that has recently been approved
by the FDA for the treatment of major depressive disorder (MDD). It is a selective serotonin …

Notwithstanding the high prevalence, functional burden, negative consequences and risk of
chronicity of major depressive disorder, few innovative medications have been developed in …

Vortioxetine is a novel drug for the treatment of major depressive disorder (MDD). It has
been reported that vortioxetine exhibits positive effect on the acute stage of MDD, while it …

Introduction: Vortioxetine is an antidepressant with multimodal activity which has shown
efficacy in major depressive disorder (MDD) patients in six of ten short-term, randomized …

Introduction Major depressive disorder (MDD) is a highly prevalent and burdensome
condition. This study aims to evaluate the effectiveness, tolerability, and safety of vortioxetine …

Objective: The primary objective of this study was to evaluate the safety and tolerability of the
investigational drug vortioxetine (Lu AA21004) in the long-term treatment of patients with …

Objective: To evaluate the clinical literature and potential clinical role of vortioxetine
(Brintellix) for the treatment of major depressive disorder (MDD). Data Sources: A MEDLINE …